The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Normally this gene, BCL11A, shuts off after birth and adult hemoglobin takes ... but it’s not necessarily the best choice for all gene-editing applications. One challenge of Cas9 is that it must be ...
Additionally, the Company is conducting ongoing research to enable in vivo editing of hematopoietic ... specific enhancer region of the BCL11A gene. This edit results in the production of ...
MarketBeat on MSN26d
MaxCyte: Building the Future of Cell and Gene Therapy InnovationGene editing tools like CRISPR/Cas-9 molecular scissors are delivered ... Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin. The edited genes are infused ...
Gene editing tools like CRISPR/Cas-9 molecular scissors ... Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin. The edited genes are infused into ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback